Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

New England Journal of Medicine

Volumn 351, Issue 7, 2004, Pages 657-667

  Jamieson, Catriona H M ^a   Ailles, Laurie E ^a   Dylla, Scott J ^a   Muijtjens, Manja ^a   Jones, Carol ^a   Zehnder, James L ^a   Gotlib, Jason ^a   Li, Kevin ^a   Manz, Markus G ^a   Keating, Armand ^b   Sawyers, Charles L ^c   Weissman, Irving L ^a,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXIN; BCR ABL PROTEIN; BETA CATENIN; IMATINIB; LENTIVIRUS VECTOR; LYMPHOID ENHANCER FACTOR 1; T CELL FACTOR PROTEIN; ANTINEOPLASTIC AGENT; CTNNB1 PROTEIN, HUMAN; CYTOSKELETON PROTEIN; DNA BINDING PROTEIN; LEF1 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RNA; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR;

ARTICLE; BLAST CELL CRISIS; BONE MARROW CELL; CELL RENEWAL; CHRONIC MYELOID LEUKEMIA; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE COURSE; ERYTHROID CELL; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSDUCTION; GRANULOCYTE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; LEUKEMOGENESIS; MACROPHAGE; MAJOR CLINICAL STUDY; MEGAKARYOCYTE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STEM CELL; ADULT; AGED; CLONOGENIC ASSAY; CYTOLOGY; DRUG RESISTANCE; FEMALE; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BETA CATENIN; BLAST CRISIS; COLONY-FORMING UNITS ASSAY; CYTOSKELETAL PROTEINS; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; GRANULOCYTES; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LYMPHOID ENHANCER-BINDING FACTOR 1; MACROPHAGES; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 3943088431     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa040258     Document Type: Article

References (58)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497.
2. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243:290-3.
3. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985;315:550-4.
4. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986;233:212-4.
5. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079-82.
6. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247:824-30.
7. Gishizky ML, Johnson-White J, Witte ON. Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice. Proc Natl Acad Sci U S A 1993;90:3755-9.
8. Jaiswal S, Traver D, Miyamoto T, Akashi K, Lagasse E, Weissman IL. Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias. Proc Natl Acad Sci U S A 2003;100:10002-7.
9. Huettner CS, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 2000;24:57-60.
10. Era T, Witte ON. Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate. Proc Natl Acad Sci U S A 2000;97:1737-42.
11. Huettner CS, Koschmieder S, Iwasaki H, et al. Inducible expression of BCR/ABL using human CD34 regulatory elements results in megakaryocytic myeloproliferative syndrome. Blood 2003;102:3363-70.
12. Udomsakdi C, Eaves CJ, Swolin B, Reid DS, Barnett MJ, Eaves AC. Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level. Proc Natl Acad Sci U S A 1992;89: 6192-6.
13. Sirard C, Lapidot T, Vormoor J, et al. Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase whereas leukemic SRC are detected in blast crisis. Blood 1996;87: 1539-48.
14. Graham SJ, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319-25.
15. Goldman JM, Melo JV. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 2003;349:1451-64.
16. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40.
17. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
18. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-32.
19. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
20. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003;112:831-43.
21. Miyamoto T, Weissman IL, Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci U S A 2000;97:7521-6.
22. Chomel JC, Brizard F, Veinstein A, et al. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation. Blood 2000;95:404-8.
23. Bose S, Deninger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998;92:3362-7.
24. Jamieson CHM, Passegue E, Weissman IL. Leukemia and leukemic stem cells. In: Gage R, ed. Stem cells in the nervous system: functional and clinical implications. Berlin: Springer-Verlag, 2004:157-82.
25. Passegue E, Jamieson CHM, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci U S A 2003;100:11842-9.
26. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
27. Reya T, Duncan AW, Ailles L, et al. A role for Wnt signalling in self-renewal of hematopoietic stem cells. Nature 2003;423:409-14.
28. Willert K, Brown JD, Danenberg E, et al. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 2003; 423:448-52.
29. Nusse R, van Ooyen A, Cox D, Fung YK, Varmus H. Mode of proviral integration of a putative mammary oncogene (int-1) on mouse chromosome 15. Nature 1984;307: 131-6.
30. Nusse R. Wnts and Hedgehogs: lipid-modified proteins and similarities in signaling mechanisms at the cell Surface. Development 2003;130:5297-305.
31. van Noort M, Meeldijk J, van der Zee R, Destree O, Clevers H. Wnt signaling controls the phosphorylation status of β-catenin. J Biol Chem 2002;277:17901-5.
32. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349: 2483-94.
33. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a β-catenin-Tcf complex in ApC-/-colon carcinoma. Science 1997;275:1784-7.
34. Morin PJ, Sparks AB, Korinek V, et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 1997;275:1787-90.
35. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of β-catenin by genetic defects in melanoma cell lines. Science 1997;275:1790-2.
36. Rask K, Nilsson A, Brannstrom M, et al. Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta. Br J Cancer 2003;89: 1298-304.
37. Uematsu K, He B, You L, Xu Z, McCormick F, Jablons DM. Activation of the Wnt pathway in non small cell lung cancer: evidence of disheveled overexpression. Oncogene 2003;22:7218-21.
38. Baum CM, Weissman IL, Tsukamoto AS, Buckle AM, Peault B. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci U S A 1992;89: 2804-8.
39. Uchida N, Sutton RE, Friera AM, et al. HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells. Proc Natl Acad Sci U S A 1998;95:11939-44.
40. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 2000;404:193-7.
41. Manz MG, Miyamoto T, Akashi K, Weissman IL. Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci U S A 2002;99: 11872-7.
42. Kondo M, Wagers AJ, Manz MG, et al. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu Rev Immunol 2003;21:759-806.
43. Domen J, Weissman IL. Hematopoietic stem cells need two signals to prevent apoptosis; BCL-2 can provide one of these, Kitl/c-Kit signaling the other. J Exp Med 2000;192:1707-18.
44. Orkin SH, Zon LI. Hematopoiesis and stem cells: plasticity versus developmental heterogeneity. Nat Immunol 2002;3:323-8.
45. Mikkola HK, Klintman J, Yang H, et al. Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene. Nature 2003;421:547-51.
46. Park IK, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003;423:302-5.
47. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukemic stem cells. Nature 2003;423: 255-60.
48. Raaijmakers MH, van Emst L, de Witte T, Mensink E, Raymakers RA. Quantitative assessment of gene expression in highly purified hematopoietic cells using real-time reverse transcriptase polymerase chain reaction. Exp Hematol 2002;30:481-7.
49. Jones CD, Yeung C, Zehnder JL. Comprehensive validation of a real-time quantitative bcr-abl assay for clinical laboratory use. Am J Clin Pathol 2003;120:42-8.
50. Schmelz EM, Roberts PC, Kustin EM, et al. Modulation of intracellular β-catenin localization and intestinal tumorigenesis in vivo and in vitro by sphingolipids. Cancer Res 2001;61:6723-9.
51. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000;25:217-22.
52. Traver D, Akashi K, Weissman IL, Lagasse E. Mice defective in two apoptotic pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity 1998;9:47-57.
53. Afar DE, McLaughlin J, Sherr CJ, Witte ON, Roussel MF. Signaling by ABL oncogenes through cyclin D1. Proc Natl Acad Sci U S A 1995;92:9540-4.
54. Afar DE, Goga A, McLaughlin J, Witte ON, Sawyers CL. Differential complementation of Bcr-Abl point mutants with c-Myc. Science 1994;264:424-6.
55. Schroeder JA, Adriance MC, Thompson MC, Camenisch TD, Gendler SJ. MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene 2003;22:1324-32.
56. Haraguchi K, Nishida A, Ishidate T, Akiyama T. Activation of beta-catenin-TCF-mediated transcription by non-receptor tyrosine kinase v-Src. Biochem Biophys Res Commun 2004;313:841-4.
57. Antonchuk J, Sauvageau G, Humphries RK. HOXB4-induced expansion of adult hematopoietic stem cells ex vivo. Cell 2002; 109:39-45.
58. Varnum-Finney B, Xu L, Brashem-Stein C, et al. Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch 1 signaling. Nat Med 2000;6:1278-81.